Journal of Pharmaceutical Analysis · 2023 · 60 citations · 12 references
MedicineOncologyPharmacologyEpigeneticsGene ExpressionMolecular OncologyCancer GenomicsCancer ImmunotherapyCancer TranscriptomicsLung Cancer PharmacotherapyProtein SynthesisTargeted Cancer TherapyGenome-wide CharacterizationNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 Inhibitors
In non-small cell lung cancer (NSCLC), the heterogeneity promotes drug resistance, and the restricted expression of programmed death-ligand 1 (PD-L1) limits the immunotherapy benefits. Based on the mechanisms related to translation regulation and the association with PD-L1 of methyltransferase-like 3 (METTL3), the novel small-molecule inhibitor STM2457 is assumed to be useful for the treatment of NSCLC. We evaluated the efficacy of STM2457 in vivo and in vitro and confirmed the effects of its inhibition on disease progression. Next, we explored the effect of STM2457 on METTL3 and revealed its effects on the inhibition of catalytic activity and upregulation of METTL3 protein expression. Importantly, we described the genome-wide characteristics of multiple omics data acquired from RNA sequencing, ribosome profiling, and methylated RNA immunoprecipitation sequencing data under STM2457 treatment or METTL3 knockout. We also constructed a model for the regulation of the translation of METTL3 and PD-L1. Finally, we found PD-L1 upregulation by STM2457 in vivo and in vitro. In conclusion, STM2457 is a potential novel suppressor based on its inhibitory effect on tumor progression and may be able to overcome the heterogeneity based on its impact on the translatome. Furthermore, it can improve the immunotherapy outcomes based on PD-L1 upregulation in NSCLC.
12
The m 6 A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells
Shuibin Lin, Junho Choe, Peng Du et al. · Molecular Cell · 2016 · 1.6K citations · Full text
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
Eliza Yankova, Wesley Blackaby, Mark R. Albertella et al. · Nature · 2021 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +13
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2022 · 843 citations
Medicine, Immunology, Oncology +17
mRNA circularization by METTL3–eIF3h enhances translation and promotes oncogenesis
Junho Choe, Shuibin Lin, Wen Cai Zhang et al. · Nature · 2018 · 797 citations